Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP, Czarnogorski M, Dalessandro M, D'Amico R, Nwafor T, Williams W, Merrill D, Wang Y, Stassek L, Wohlfeiler MB, Sinclair GI, Mena LA, Thedinger B, Flamm JA, Benson P, Spreen WR. Garris CP, et al. Among authors: nwafor t. J Int AIDS Soc. 2022 Sep;25(9):e26006. doi: 10.1002/jia2.26006. J Int AIDS Soc. 2022. PMID: 36097674 Free PMC article. Clinical Trial.
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Czarnogorski M, Garris CP, Dalessandro M, D'Amico R, Nwafor T, Williams W, Merrill D, Wang Y, Stassek L, Wohlfeiler MB, Sinclair GI, Mena LA, Thedinger B, Flamm JA, Benson P, Spreen WR. Czarnogorski M, et al. Among authors: nwafor t. J Int AIDS Soc. 2022 Sep;25(9):e26003. doi: 10.1002/jia2.26003. J Int AIDS Soc. 2022. PMID: 36094142 Free PMC article. Clinical Trial.
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
Czarnogorski M, Benn P, McCoig C, Nwafor T, Griffith S, Sutton K, Harrington C, Saggu P, Yague I, Williams W, Español CM, Goodchild J, Fricker J, Patel P, D'Amico R. Czarnogorski M, et al. Among authors: nwafor t. J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):157-161. doi: 10.1097/QAI.0000000000003031. Epub 2022 Jun 4. J Acquir Immune Defic Syndr. 2022. PMID: 36094481
Exploration of the diversity of multi-drug resistant Mycobacterium tuberculosis complex in Lagos, Nigeria using WGS: Distribution of lineages, drug resistance patterns and genetic mutations.
Noorizhab MNF, Zainal Abidin N, Teh LK, Tang TH, Onyejepu N, Kunle-Ope C, Tochukwu NE, Sheshi MA, Nwafor T, Akinwale OP, Ismail AI, Nor NM, Salleh MZ. Noorizhab MNF, et al. Among authors: nwafor t. Tuberculosis (Edinb). 2023 May;140:102343. doi: 10.1016/j.tube.2023.102343. Epub 2023 Apr 16. Tuberculosis (Edinb). 2023. PMID: 37080082
11 results